Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.
Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, Samri A, Sáez-Cirión A, Hocqueloux L, Lascoux-Combe C, Allavena C, Goujard C, Valantin MA, Leplatois A, Meyer L, Rouzioux C, Autran B; OPTIPRIM ANRS-147 Study Group. Chéret A, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2015 Jul;70(7):2108-20. doi: 10.1093/jac/dkv084. Epub 2015 Apr 21. J Antimicrob Chemother. 2015. PMID: 25900157 Clinical Trial.
Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort.
Ghosn J, Deveau C, Chaix ML, Goujard C, Galimand J, Zitoun Y, Allègre T, Delfraissy JF, Meyer L, Rouzioux C; ANRS PRIMO Cohort. Ghosn J, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2010 Apr;65(4):741-8. doi: 10.1093/jac/dkq035. Epub 2010 Feb 18. J Antimicrob Chemother. 2010. PMID: 20167586
Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE).
Avettand-Fenoel V, Bouteloup V, Mélard A, Fagard C, Chaix ML, Leclercq P, Chêne G, Viard JP, Rouzioux C; members of the ETOILE study. Avettand-Fenoel V, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2010 Oct;65(10):2212-4. doi: 10.1093/jac/dkq282. Epub 2010 Jul 28. J Antimicrob Chemother. 2010. PMID: 20667886
Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells.
Descours B, Avettand-Fenoel V, Blanc C, Samri A, Mélard A, Supervie V, Theodorou I, Carcelain G, Rouzioux C, Autran B; ALT ANRS CO15 Study Group. Descours B, et al. Among authors: rouzioux c. Clin Infect Dis. 2012 May;54(10):1495-503. doi: 10.1093/cid/cis188. Epub 2012 Mar 22. Clin Infect Dis. 2012. PMID: 22441653
Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, Niang M, Mille C, Le Moal G, Viard JP, Rouzioux C; AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS). Hocqueloux L, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2013 May;68(5):1169-78. doi: 10.1093/jac/dks533. Epub 2013 Jan 20. J Antimicrob Chemother. 2013. PMID: 23335199
A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection.
Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, Blanc C, Lascoux-Combe C, Slama L, Allegre T, Allavena C, Yazdanpanah Y, Duvivier C, Katlama C, Goujard C, Seksik BC, Leplatois A, Molina JM, Meyer L, Autran B, Rouzioux C; OPTIPRIM ANRS 147 study group. Bacchus C, et al. Among authors: rouzioux c. PLoS One. 2013 May 14;8(5):e64219. doi: 10.1371/journal.pone.0064219. Print 2013. PLoS One. 2013. PMID: 23691172 Free PMC article.
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miailhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group. Chéret A, et al. Among authors: rouzioux c. Lancet Infect Dis. 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6. Epub 2015 Feb 18. Lancet Infect Dis. 2015. PMID: 25701561 Clinical Trial.
Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial).
Piroth L, Moinot L, Yeni P, Avettand-Fénoel V, Reynes J, Girard PM, Marchou B, Georget A, Rouzioux C, Autran B, Duvillard L, Chêne G, Fagard C; ANRS 141 TIPI Trial Study Group. Piroth L, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2016 Feb;71(2):490-6. doi: 10.1093/jac/dkv369. Epub 2015 Nov 14. J Antimicrob Chemother. 2016. PMID: 26568566 Clinical Trial.
Polyfunctional HIV-specific T cells in Post-Treatment Controllers.
Samri A, Bacchus-Souffan C, Hocqueloux L, Avettand-Fenoel V, Descours B, Theodorou I, Larsen M, Saez-Cirion A, Rouzioux C, Autran B; ANRS VISCONTI study group. Samri A, et al. Among authors: rouzioux c. AIDS. 2016 Sep 24;30(15):2299-302. doi: 10.1097/QAD.0000000000001195. AIDS. 2016. PMID: 27428742
510 results